These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7614742)
1. [Clinical features and factors related to the functional prognosis in Meige's syndrome]. Kamitsukasa I; Yamada T; Tokumaru Y; Hirayama K Rinsho Shinkeigaku; 1995 Mar; 35(3):231-6. PubMed ID: 7614742 [TBL] [Abstract][Full Text] [Related]
3. Clinical and demographic features of Meige's syndrome. Sharma AK; Behari M; Ahuja GK J Assoc Physicians India; 1996 Sep; 44(9):645-7. PubMed ID: 9251378 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin in Meige's syndrome: A video-based case series. Pandey S; Sharma S Neurol India; 2018; 66(1):71-76. PubMed ID: 29322963 [TBL] [Abstract][Full Text] [Related]
5. Levetiracetam in Meige's syndrome. Yardimci N; Karatas M; Kilinc M; Benli S Acta Neurol Scand; 2006 Jul; 114(1):63-6. PubMed ID: 16774630 [TBL] [Abstract][Full Text] [Related]
6. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome. Bastola P; Chaudhary M; Agrawal JP; Shah DN Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735 [TBL] [Abstract][Full Text] [Related]
8. [Clinical and electromyographical features of 24 cases of Meige's syndrome]. Hirose K; Uono M; Tsubaki T Rinsho Shinkeigaku; 1984 Sep; 24(9):930-40. PubMed ID: 6518718 [No Abstract] [Full Text] [Related]
9. Blepharospasm--oromandibular dystonia (Meige's syndrome) misdiagnosed as secondary hemifacial spasm. Gottlieb JS; May M Am J Otol; 1984 Jan; 5(3):206-10. PubMed ID: 6720874 [TBL] [Abstract][Full Text] [Related]
10. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Van den Bergh P; Francart J; Mourin S; Kollmann P; Laterre EC Muscle Nerve; 1995 Jul; 18(7):720-9. PubMed ID: 7783762 [TBL] [Abstract][Full Text] [Related]
11. Meige's syndrome and hemichorea associated with hyperthyroidism. Miao J; Liu R; Li J; Du Y; Zhang W; Li Z J Neurol Sci; 2010 Jan; 288(1-2):175-7. PubMed ID: 19883923 [TBL] [Abstract][Full Text] [Related]
12. Neuroleptic-induced Meige's syndrome following akathisia: pharmacologic characteristics. Hayashi T; Furutani M; Taniyama J; Kiyasu M; Hikasa S; Horiguchi J; Yamawaki S Psychiatry Clin Neurosci; 1998 Aug; 52(4):445-8. PubMed ID: 9766696 [TBL] [Abstract][Full Text] [Related]
13. Use of botulinum toxin in Meige's disease. Maurri S; Brogelli S; Alfieri G; Barontini F Riv Neurol; 1988; 58(6):245-8. PubMed ID: 3247565 [TBL] [Abstract][Full Text] [Related]
14. [Craniocervical dystonia and facial hemispasm: clinical and pharmacological characteristics of 52 patients]. Astarloa R; Morales B; Peñafiel N; Rábano J; de Yébenes JG Rev Clin Esp; 1991 Nov; 189(7):320-4. PubMed ID: 1767088 [TBL] [Abstract][Full Text] [Related]
15. Melatonin secretion and the pathophysiology of Meige's disease (idiopathic orofacial dystonia): a hypothesis. Sandyk R; Kay SR Funct Neurol; 1990; 5(2):165-70. PubMed ID: 1977665 [TBL] [Abstract][Full Text] [Related]